Experts predict that the fourth wave with bio-economy as the main body will have a huge boost to economic development and human progress. After more than 20 years of development, China’s biotechnology industry has also initially established a complete biotechnology research and development system, and the bioeconomy has begun to emerge. There are about 500 enterprises involving modern biotechnology in China, employing more than 50,000 people and growing at an annual rate of nearly 100 companies. However, while biotechnology has made significant progress, China's biotechnology industry has also had to face the huge gap with the developed countries and the "bottleneck" constraints in the development process. The gap shows many aspects compared with the development of the international biotechnology industry, the gap between China's biotechnology industry and the international level is obvious. The specific performance is as follows: The lack of independent intellectual property rights It is understood that biological products are mostly invented by developed countries such as Europe and the United States, and most of the varieties currently produced in China are imitation products with expired patents, so they are also compared with foreign countries in terms of production technology. There is a certain gap. The bio-industry is basically still in the phase of tracking research and imitation. On the one hand, there are too few proprietary intellectual property products, but on the other hand, there is insufficient understanding of intellectual property rights. In the Americas, when biotechnology high-tech companies are created, in the first and second phases of financing (ie, seed funding period and venture investment period), technology investors generally control more than 50% of the equity. The capital investor is a minority shareholder. This situation is very common in North America. With the continuous expansion of the enterprise scale and the continuous increase of corporate financing, entrepreneurs (technology owners) have gradually lost absolute control of ownership, but the enterprise itself is a complete modern enterprise mechanism. Our country still has flaws in this issue, which directly shows that intangible assets are below 35% in the ownership structure. Enterprise equipment is lagging far behind China's enterprises engaged in biotechnology are mostly small and medium-sized enterprises, and they are lagging behind in supporting technologies and equipment such as important instruments, equipment, and reagents required for the development of biotechnology industry and industries. They mainly rely on foreign imports. The supporting technology and equipment of the biotechnology industry have two major characteristics. First, it involves the intersection of multi-disciplinary and multi-technology fields. Second, the vast majority of companies that manufacture and operate specialized instruments and equipment have an international market. Only international markets can occupy the international market. Survival and development in competition. At present, China does not have the capability to independently develop and produce equipment and occupy international markets. The disorderly competition phenomenon is serious. There is currently no national organization or management organization that administers the research, development, and industrialization of the biotechnology industry. There is no overall strategic deployment. Companies engaged in biotechnology are affiliated to various competent authorities, belonging to medicine, light industry, chemical industry, and also to departments such as universities and colleges. These enterprises are self-government. Some old people do not make contact with each other and their forces cancel each other out; taking into account their respective interests, There are fragmentation phenomena. Some local governments have blindly started construction of their own businesses for their own benefit, resulting in low-level duplication, and the biotechnology industry lacks overall advantages. The fact that taxation of bio-enterprises is relatively high is that bio-enterprises have higher taxes, which is higher than traditional industries. Experts believe that the cost structure of bio-enterprise products is different from that of the general industry, and the proportion of direct material costs that can be deducted continues to decrease. The indirect costs mainly include research and development costs, technology development fees, pilot-use costs, and technology-introduction costs. As the proportion continues to rise, these expenditures generally cannot be invoiced for value-added tax, and they cannot be included in the input tax amount. This results in higher technical content, a heavier tax burden and higher costs, which seriously restricts the development of enterprises. The "Exempt Two, Three, and Three" policy also does not suit the development of bio-enterprises, because bio-pharmaceutical companies require a long period of research and development. From establishment to profitability, it takes a long time for companies to set up products for at least 3 to 5 years before they are allowed to go on sale. The lack of bidirectional and talented people Like other high-tech industries, the development of the biotechnology industry requires five fundamental elements, namely, technology, capital, talent, management and policy. At present, the core issue of China's biotechnology industry development is the need for a large number of bi-directional talents who understand both biotechnology and enterprise management. The biotechnology industry is a high-input, high-risk, and high-return industry, with high technical thresholds, high talent thresholds, and relatively long investment cycles. Biological science and technology is a typical experimental discipline. University graduates can only be regarded as just getting started. Only after graduates graduated 5 or even 10 years can they have product and technology development capabilities. Due to the long training cycle for research and development personnel, a large number of outstanding scientific researchers are stranded abroad. There is a lack of talented people in the country, especially two-way talents who understand both production technology and enterprise management. Most university education in our country is exam-oriented education. Due to factors such as disciplines and academic systems, undergraduates and postgraduates trained under the current system are more focused on basic theories. The ability to work and think independently is flawed. Meet the needs of the development of modern biotechnology companies. In the future, the bottleneck needs to be broken through by experts' suggestions. According to the trend of development of the global biotechnology industry and China's specific conditions, the “bottleneck†in terms of macro-control, product development, tax burden, shortage of talent, etc. needs to be broken. Therefore, it must be done from the following four aspects. Efforts to Strengthen Macro-regulation and Control The bio-innovation and the industrialization of scientific research results are systematic projects that rely on effective policies for integration. According to the present situation of China's bio-industry, which is relatively decentralized, small in size, and weak in technical strength, it is necessary to make full use of the adjustment methods of both government and market resources to revitalize the stock of technologies, equipment and facilities, and talents in China, so that all aspects of Advantageous systems are effectively integrated. Relevant state agencies should provide overall planning and coordination guidance for the nation’s biotechnology industry and industrial development, so as to achieve overall coordination, avoid multi-headed and multi-government, and achieve unified, simple, and efficient decision-making, coordination, and implementation systems. Increase the cost of product development China's pharmaceutical companies, including bio-pharmaceutical companies, are currently spending too little on new product development. In foreign countries, research and development costs account for more than 10% of total sales, and some international multinational giants have reached 30%, while the research and development costs of pharmaceutical companies in China account for only about 1% of total sales. %about. The insufficiency of technological development costs severely restricts the development of China's biotechnology industry. Therefore, under the condition that our country's capital market is imperfect, it is necessary for the government to increase investment and establish an incubator of major national biotechnology industry projects to accelerate the pace of industrialization of results. At the same time, biotechnology companies should be encouraged to expand their financing channels, fully utilize financial credit, introduce foreign capital, government financial support, capital market risk investment, and various forms of financial resources for biological industry development. Formulate tax support policies The state should encourage enterprises to develop and produce biological products in the country. If the general taxpayer sells biological products developed and produced by himself, the value-added tax shall be levied at a statutory rate of 17%, and the portion exceeding 3% of the actual tax rate shall be refunded immediately. The enterprise shall use it for research and development of biological products and expand reproduction. In addition, bio-enterprises established in China may also consider preferential corporate income tax policies; newly-established bio-enterprises may benefit from “two exemptions and three and a half†preferential corporate income tax from the profit-making year; In the case of bio-enterprises that do not enjoy tax-free concessions for the year, corporate income tax is levied at a tax rate of 10%. Talent strategy is a two-pronged approach. On the issue of talent, especially on the issue of two-way talent, we must implement a two-pronged strategy. In cultivating talents, we must not only focus on cultivating basic theories, but should also pay attention to the cultivation of hands-on capabilities and independent thinking. From the employment situation of college students in recent years, it can be seen that many undergraduates and even postgraduates with advanced theoretical abilities are not favored by enterprises. Instead, they welcome the students of higher vocational and technical schools with practical abilities. It is necessary to establish a master's degree in biotechnology, an industrial doctorate, and an industrial post-doctoral system through the new school-running mechanism, and cultivate a large number of talents with first-class industrial technology and management. At the same time, overseas biotechnological talents should also be properly introduced, especially expert talents with good academics and successful careers, so that they can return to the country to use their skills as well as the role of leading figures. While paying attention to cultivating and introducing talented people, we must not ignore "retaining people." After some enterprises introduce talents, there are often brain drains, mainly because the promised conditions are not fulfilled, and the entrepreneurial environment is not good. Therefore, it is necessary to make tilts in terms of policies, funding, etc., to fully care about the life, work, and study of talented people, so that they can work at ease and actively contribute their wisdom and wisdom to the company.
Intramedullary K Wire,Medical K Wire,K Wire Drill
Disposable Grasping Forceps CO.,Ltd , http://www.nsmedicalequipment.com